

Puerto Rico's Secretary of Economic Development obtains first-hand information on Sartorius investments in Yauco

- **Expansion of production capacity close to completion**

Göttingen, April 5, 2019 – The Secretary of Economic Development and Commerce of Puerto Rico, Manuel Laboy, recognized Sartorius' commitment in investing in his country. "We are happy that Sartorius has considerably invested in Yauco. Its plant represents one of the largest investments made and is therefore important for the economic development of the region," commented Laboy during a visit to Sartorius Campus in Göttingen, Germany. He received first-hand information about membrane technologies as well as filter products that will be increasingly manufactured at the Sartorius plant in Yauco, Puerto Rico.

Sartorius, a leading international partner of biopharmaceutical research and the industry, has invested more than 100 million U.S. dollars to double production capacity at its Puerto Rican site covering nearly 190,000 square meters or around 2 million square feet. Expansion of the plant that commenced in 2016 is scheduled to be completed in the second quarter of 2019. Located in the southwest of Puerto Rico, the manufacturing facility in Yauco primarily supplies the U.S. market, which is among the focal growth regions of Sartorius. "For us, expansion of the plant is both a financial and a strategic investment. We are therefore expanding our manufacturing network, which will be giving us more flexibility for further growth, above all in the Americas region," said Rainer Lehmann, member of the Executive Board and Chief Financial Officer.

Since 1982, Sartorius has been manufacturing filters in Yauco and, since 2012, aseptic bags in addition. Expansion of this site will more than double production of single-use bags for biopharmaceutical manufacture and of membrane filters, as well as approximately triple cleanroom capacities. Currently, more than 450 people work at Sartorius in Yauco, and the number of employees is slated to further increase.

Follow Sartorius on [Twitter](#) @Sartorius_Group and on [LinkedIn](#).

A profile of Sartorius

The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2018, Sartorius earned sales revenue of around 1.57 billion euros. Currently, more than 8,100 people work at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Timo Lindemann | Corporate Communications

+49 (0)551.308.4724 | timo.lindemann@sartorius.com | www.sartorius.com